Castellano | Euskara | Français | English
DAR No 1: Glycopyrronium bromide. Seebri Breezhaler®, Enurev Breezhaler® in COPD
Share it
We´re not breathing anything new under the sun
- Glycopyrronium bromide is an inhaled long-acting muscarinic antagonist (LAMA) approved for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD).
- The only head-to-head trial published to date showed noninferiority vs tiotropium but not superiority.
- The average change with respect to baseline FEV1 trough was 103 mL (glycopyrronium) vs 99 mL (tiotropium), but there was no clinical relevance (120 mL).
- Safety profile remains inconclusive given the short duration of the trials, the chronic nature of the disease and lack of data with regard to its cardiovascular safety profile.
